Patupilone (Epothilone B)

For research use only.

Catalog No.S1364 Synonyms: EPO906

11 publications

Patupilone (Epothilone B) Chemical Structure

CAS No. 152044-54-7

Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.

Selleck's Patupilone (Epothilone B) has been cited by 11 publications

4 Customer Reviews

  • Matrigel invasion assay of H1299 cells treated with SDF-1α or SDF-1α plus Epothilone B prior to 0 or 2 Gy irradiation. After the treatment for 12 h, the H1299 cells that migrated to the bottom surface of the membrane were stained with Giemsa, and the number of migrated cells was calculated manually.

    Oncotarget, 2015, 6(13):10893-907.. Patupilone (Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9.. Patupilone (Epothilone B) purchased from Selleck.

  • Cells were seeded in 96 well paltes, and then treated with the indicated concentration of Epothilone B for 48 h. Cell survival was measured by a standarad MTT assay.

     

     

    Dr. Helen Sadik of Johns Hopkins University. Patupilone (Epothilone B) purchased from Selleck.

    Combination treatment with epothilone B and ABT-737 inhibited PI3K/AKT/mTOR pathway. SKOV-3 cells were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination, OVCAR-8 cells were treated with epothilone B (0.3 nM), ABT-737 (3 μM), or the combination, SGC-7901 were treated with epothilone B (0.4 nM), ABT-737 (5 μM), or the combination. Cells were exposed to compounds for 48 h, after which protein extracts were immunoblotted with specified antibodies for p-4E-BP-1, p-mTOR, p-AKT, caspase-3, PARP and β-actin.

    J Cancer Res Clin Oncol, 2016, 142(11):2281-9. Patupilone (Epothilone B) purchased from Selleck.

Purity & Quality Control

Choose Selective Microtubule Associated Inhibitors

Biological Activity

Description Patupilone (EPO906, Epothilone B) is a paclitaxel-like microtubule-stabilizing agent with EC0.01 of 1.8 μM. Phase 2.
Targets
Tubulin [1]
(Cell-free assay)
1.8 μM(EC0.01)
In vitro

Epothilone B shows better activity than Epothilone A. The EC0.01 of Epothilone B is 1.8 μM. Epothilone B potently inhibits cell proliferation in HCT116 cells, with IC50 of 0.8 nM. [1] Epothilone B induces mitotic arrest and displays cytotoxicity in KB3-1, KBV-1, Hela, and Hs578T cells, with IC50 of 3 nM to 92 nM. Epothilone B competes with Taxol in binding to microtubules, with IC50 of 3.3 μM. [2] In MCF-7 cells overexpressing GFP-α-tubulin, Epothilone B (3.5 nM) efficiently blocks microtubule dynamics. Meanwhile, Epothilone B induces mitotic arrest with IC50 of 3.5 nM. [3] In multiple myeloma (MM) cells, including RPMI 8226, U266, MM.1S, LR5, and MR20, Epothilone B directly suppresses proliferation with IC50 of 1 nM to 10 nM. Similarly, Epothilone B (10 nM) also induces cell cycle arrest and apoptosis. [4] A recent study reveals that, in ovarian cancer Hey cells, Epothilone B (5 nM–100 nM) enhances surface epithelial cell adhesion antigen (EpCAM), without affecting the transcription or the total cellular level of EpCAM. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human LC-2-ad cell NGrhPY5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MoOyTY5pcWKrdHnvckBw\iCqdX3hckBNSy1{LXHkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44P2VvME[g{txO NYrYOWFwW0GQR1XS
human A431 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mn7WTY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OT64OoUuODZizszN MXzTRW5ITVJ?
human SW1710 cell MYnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NH;MZWpKdmirYnn0bY9vKG:oIHj1cYFvKFOZMUexNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvOTSnLUC1JO69VQ>? NIKyZ41USU6JRWK=
human Daoy cell M3;2WWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{myVGlvcGmkaYTpc44hd2ZiaIXtZY4hTGGxeTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H589yNKEmFNUC9Nk44O2VvMEWg{txO MmD3V2FPT0WU
human BFTC-905 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M13kWWlvcGmkaYTpc44hd2ZiaIXtZY4hSk[WQz25NFUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njl7ZT2wOUDPxE1? NEfUPY5USU6JRWK=
human A375 cell M1H1e2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnsTY5pcWKrdHnvckBw\iCqdX3hckBCOzd3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NXWtNFUh|ryP NVK3[VNPW0GQR1XS
human RKO cell NETmbVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NXS3boJSUW6qaXLpeIlwdiCxZjDoeY1idiCUS1:gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ4\S1yNTFOwG0> Ml3EV2FPT0WU
human KYSE-510 cell Mn3ES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MnXFTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUWxNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVcvOzinLUC1JO69VQ>? MorsV2FPT0WU
human HLE cell NF7DNmdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlHGTY5pcWKrdHnvckBw\iCqdX3hckBJVEViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD16LkK2[U0xPSEQvF2= NF;FVnpUSU6JRWK=
human MCF7 cell NGL1PWxIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2fqbGlvcGmkaYTpc44hd2ZiaIXtZY4hVUOINzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUiuOlZmNTB3IN88US=> NYe4SolNW0GQR1XS
human 786-0 cell Mli4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIOwdHFKdmirYnn0bY9vKG:oIHj1cYFvKDd6Nj2wJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOSCwTR?= M1HienNCVkeHUh?=
human TE-8 cell NGnvT2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHjIVVhKdmirYnn0bY9vKG:oIHj1cYFvKFSHLUigZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyOSCwTR?= MX;TRW5ITVJ?
ovarian carcinoma 1A9 cell MlnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M131PGlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IH;2ZZJq[W5iY3HyZ4lvd22jIEHBPUBk\WyuIHfyc5d1cA>? M1i3bFE3OTN2OUK4
human PANC-03-27 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXydoo5UW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xN|Ih|ryP NFTYTY1USU6JRWK=
human VMRC-RCZ cell M{\GcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlfoTY5pcWKrdHnvckBw\iCqdX3hckBXVVKFLWLDXkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTN4IN88US=> Ml[3V2FPT0WU
human IGROV-1 cell MnnWS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWG5NVZUUW6qaXLpeIlwdiCxZjDoeY1idiCLR2LPWk0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zNU[g{txO M1r4fnNCVkeHUh?=
human MG-63 cell M{j4b2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkDnTY5pcWKrdHnvckBw\iCqdX3hckBOTy14MzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVY2KM7:TR?= M{n4[3NCVkeHUh?=
human SIG-M5 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXHY[G5iUW6qaXLpeIlwdiCxZjDoeY1idiCVSVetUVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF4OTFOwG0> NUjzTlJCW0GQR1XS
human NCI-H650 cell NFnYd2tIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2XIOmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF5IN88US=> NEi3[phUSU6JRWK=
human PSN1 cell NFL1NodIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH\jN3pKdmirYnn0bY9vKG:oIHj1cYFvKFCVTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlE4OyEQvF2= M1G1fXNCVkeHUh?=
human PA-1 cell NHrwXJRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUnJbnRHUW6qaXLpeIlwdiCxZjDoeY1idiCSQT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yPzRizszN M33wdXNCVkeHUh?=
KB-8511 cells NYPkU444T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3rLeFczKGh? M{LWfGNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDD0bIUh\3Kxd4ToJI9nKHCjY3zpeIF5\WxvcnXzbZN1[W62IHj1cYFvKGWyaXTldo1wcWRiY3HyZ4lvd22jIHPlcIx{KEuELUi1NVEh[nliNUCgdIVz[2WwdDCoO|IhcHJiZYjwc5N2emVrLDDJR|UxRTBwMUig{txO MXmxNVE{OzB6Nh?=
KB-31 cells Mn;hS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIS2RYw4OiCq MVvDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRidHjlJIdzd3e2aDDv[kBx[WOuaYThfIVtNXOnboPpeIl3\SCqdX3hckBmeGmmZYLtc4llKGOjcnPpco9u[SClZXzsd{BMSi1|MTDifUA2OCCyZYLj[Y51KCh5MjDodkBmgHCxc4Xy[Uk> MkHTNVEyOzNyOE[=
human BHY cell Mk\FS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHfmUXVKdmirYnn0bY9vKG:oIHj1cYFvKEKKWTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk2KG6P NXj4dokzW0GQR1XS
human BB30-HNC cell NGrSTG5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= NH[0dIpKdmirYnn0bY9vKG:oIHj1cYFvKEKEM{CtTG5EKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{MEGg{txO MlPTV2FPT0WU
human HOS cell MkPDS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M1LZSmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNVUh|ryP M{HpdnNCVkeHUh?=
human 639-V cell NWPXVZJtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjLWopKdmirYnn0bY9vKG:oIHj1cYFvKDZ|OT3WJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOThizszN M{nHTnNCVkeHUh?=
human ES1 cell  Ml3XS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NXjFcIRKUW6qaXLpeIlwdiCxZjDoeY1idiCHU{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIzOSEQvF2= NHnh[FdUSU6JRWK=
human TE-15 cell  NX7Cb|JiT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXv3Z21oUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xOUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjJ3IN88US=> NF3GSGZUSU6JRWK=
human LXF-289 cell M{\jO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3\zUmlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjd5IN88US=> MX\TRW5ITVJ?
human CAL-12T cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXryXWhHUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytNVJVKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{mg{txO MUnTRW5ITVJ?
human T84 cell NUHUOJhTT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHjuWZJKdmirYnn0bY9vKG:oIHj1cYFvKFR6NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlQh|ryP NHjuXppUSU6JRWK=
human KYSE-450 cell M2LkbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF7NW2pKdmirYnn0bY9vKG:oIHj1cYFvKEu\U1WtOFUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{Nkeg{txO MWHTRW5ITVJ?
human LCLC-103H cell NVPZTYdET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MoHPTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUGwN2gh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjNzIH7N NHqyXFBUSU6JRWK=
human NCI-H810 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDNdnJKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IPFExKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|MkKg{txO MYrTRW5ITVJ?
human HUTU-80 cell NIS4RoNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1XW[mlvcGmkaYTpc44hd2ZiaIXtZY4hUFWWVT24NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ6IN88US=> M2HIZ3NCVkeHUh?=
human NCI-H460 cell NUf0OHlYT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3raWWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi0OlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN|MzFOwG0> MXvTRW5ITVJ?
human HGC-27 cell NFG3Vm5Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M1;QS2lvcGmkaYTpc44hd2ZiaIXtZY4hUEeFLUK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzhizszN MmTJV2FPT0WU
human HSC-2 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3fuVGlvcGmkaYTpc44hd2ZiaIXtZY4hUFOFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlM3OyCwTR?= NGHyTphUSU6JRWK=
human IA-LM cell NF7td41Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MYLJcohq[mm2aX;uJI9nKGi3bXHuJGlCNUyPIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zPVMh|ryP NIHySHRUSU6JRWK=
human HMV-II cell NXL4XVduT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVHJcohq[mm2aX;uJI9nKGi3bXHuJGhOXi2LSTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|k1KM7:TR?= NF;Cd|RUSU6JRWK=
human COLO-679 cell MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1\teWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz22O|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7NDFOwG0> MX3TRW5ITVJ?
human NCI-H2122 cell NF7iV5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MnrnTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKxNlIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzIN88US=> MVjTRW5ITVJ?
human CAL-39 cell MlHxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUfOOpNsUW6qaXLpeIlwdiCxZjDoeY1idiCFQVytN|kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjRzMTFOwG0> MlnEV2FPT0WU
human SW954 cell NX\SZ4Q2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60N|Yh|ryP M1LFXHNCVkeHUh?=
human LCLC-97TM1 cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnXoTY5pcWKrdHnvckBw\iCqdX3hckBNS0yFLUm3WG0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC52NESg{txO M2qxdXNCVkeHUh?=
human KYSE-270 cell MUjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MU\Jcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvMkewJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PDVizszN M2jlRXNCVkeHUh?=
human NB13 cell M4C1V2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NWP5eYpJUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PDdizszN NV\WcmNQW0GQR1XS
human SK-LMS-1 cell Mm\OS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MUjJcohq[mm2aX;uJI9nKGi3bXHuJHNMNUyPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE43PDZizszN M17aZ3NCVkeHUh?=
human SW620 cell M4\uZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkDMTY5pcWKrdHnvckBw\iCqdX3hckBUXzZ{MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOlQ5KM7:TR?= MYfTRW5ITVJ?
human HCT-15 cell MmL4S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3zibGlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUG1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE44OTdizszN MoPRV2FPT0WU
human DU-145 cell M{XsRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmH4TY5pcWKrdHnvckBw\iCqdX3hckBFXS1zNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlczOSEQvF2= NHq4N2RUSU6JRWK=
human ST486 cell NUGwcGtQT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUPJVHM1UW6qaXLpeIlwdiCxZjDoeY1idiCVVES4OkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPzJzIN88US=> NGntbmtUSU6JRWK=
human A427 cell M4XKcWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NFf3[4FKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlgzQCEQvF2= NGT3UZNUSU6JRWK=
human HT-1080 cell MXjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NEDIZYhKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh2MjFOwG0> M12xXXNCVkeHUh?=
human NCI-H2009 cell NVrEbGNHT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlH6TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKwNFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh4MjFOwG0> MUXTRW5ITVJ?
human SK-LU-1 cell MXHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnroTY5pcWKrdHnvckBw\iCqdX3hckBUUy2OVT2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE45PjZizszN NVjGZlJCW0GQR1XS
human SCC-4 cell MknzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkjoTY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPFc4KM7:TR?= MYXTRW5ITVJ?
human NCI-H1299 cell MlLNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MX7Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUK5PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDhizszN NFLLWZhUSU6JRWK=
human NH-12 cell MmHLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUPrNFlQUW6qaXLpeIlwdiCxZjDoeY1idiCQSD2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvQDlzIN88US=> NV:2TJlpW0GQR1XS
human SK-UT-1 cell NWXWe4tVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUG1R2hbUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC56OUKg{txO NIjQ[3FUSU6JRWK=
human Bel7402 MX;Qdo9tcW[ncnH0bY9vKGG|c3H5 MmHIO|IhcA>? Mnr5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCEZXy3OFAzKGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIhT2yxIHHzd4F6NCCLQ{WwQVAvQSEQvF2= NH[2NJkzOjN{MEO1OC=>
human A388 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVr6THF[UW6qaXLpeIlwdiCxZjDoeY1idiCDM{i4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PCEQvF2= MkjxV2FPT0WU
human SW982 cell NGXuU|NIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MofPTY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVk6KM7:TR?= M1joVHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo In a mouse xenograft model of RPMI 8226 cells, Epothilone B (2.5 mg/kg–4 mg/kg) prolongs survival and suppresses tumor growth. [4] Similarly, in mouse xenograft models of prostate cancer cells, including DU145 and PC3, Epothilone B at the same dose also inhibits tumor growth. [6]

Protocol

Kinase Assay:[1]
- Collapse

Tubulin polymerization assay:

Calf brain microtubule proteins (MTP) are purified, which includes approximately 15%–20% microtubule associated proteins. The buffer (MES buffer) used for the Epothilone B-microtubule studies contains 0.1 M 2-morpholinoethanesulfonic acid (MES), 1 mM EGTA, 0.5 mM MgCl2, and 3 M glycerol at pH 6.6. Samples for electron microscopy are placed on carbon-over-Parlodion-coated grids (300 mesh) and negatively stained with 2% uranyl acetate. Microtubule assembly in the presence or absence of Epothilone B is monitored spectrophotometrically by using a spectrophotometer equipped with a thermostatically regulated liquid circulator. The temperature is held at 35 °C and changes in turbidity (representative of polymer mass) are monitored at 350 nm. Effective concentration (EC0.01), defined as the interpolated concentration capable of inducing an initial slope of 0.01 OD/min rate, is calculated using the formula EC0.01 = concentration/slope and expressed as the mean with standard deviation obtained from three different concentrations.
Cell Research:[2]
- Collapse
  • Cell lines: KB3-1, KBV-1, Hela, and Hs578T cells
  • Concentrations: 0–1 μM
  • Incubation Time: 72 hours
  • Method: For mitotic block and aberrant mitosis, cells are plated either in 48-well plates (for trypan blue and cell counting) or onto coverslips. After 24 hours, cells are treated with Epothilone B and scored at regular intervals. For the cytotoxicity analysis, cells are counted and scored as trypan blue positive or negative. Concurrently, coverslips andaliquots of cells in the culture supernatant are fixed and stained with Hoechst33342 in PBS. These cells are scored for cells blocked at the G2/M transition and aberrant mitosis.
    (Only for Reference)
Animal Research:[4]
- Collapse
  • Animal Models: Mice xenograft model of RPMI 8226 cells
  • Dosages: 2.5 mg/kg–4 mg/kg
  • Administration: Inject intravenously
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 102 mg/mL (200.91 mM)
Ethanol 102 mg/mL (200.91 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
30% PEG400+0.5% Tween80+5% propylene glycol
For best results, use promptly after mixing.
5 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 507.68
Formula

C27H41NO6S

CAS No. 152044-54-7
Storage powder
in solvent
Synonyms EPO906
Smiles CC1CCCC2(C(O2)CC(OC(=O)CC(C(C(=O)C(C1O)C)(C)C)O)C(=CC3=CSC(=N3)C)C)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT00496600 Completed Drug: Patupilone|Drug: RAD001 Refractory Malignancy University of Medicine and Dentistry of New Jersey|Novartis Pharmaceuticals|National Cancer Institute (NCI)|Rutgers The State University of New Jersey July 2007 Phase 1
NCT00442741 Withdrawn Drug: Patupilone|Drug: Patupilone + Omeprazole Solid Tumors Novartis Pharmaceuticals|Novartis July 2007 Phase 1
NCT00468260 Terminated Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis May 2007 Phase 1
NCT00448396 Completed Drug: Patupilone Advanced Malignancies Novartis Pharmaceuticals|Novartis March 2007 Phase 1
NCT00426140 Completed Drug: Patupilone Advanced Malignancies|Solid Tumors Novartis Pharmaceuticals|Novartis August 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Microtubule Associated Signaling Pathway Map

Related Microtubule Associated Products

Tags: buy Patupilone (Epothilone B) | Patupilone (Epothilone B) supplier | purchase Patupilone (Epothilone B) | Patupilone (Epothilone B) cost | Patupilone (Epothilone B) manufacturer | order Patupilone (Epothilone B) | Patupilone (Epothilone B) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID